Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
From MaRDI portal
Publication:4666043
DOI10.2307/2533853zbMath1058.62585OpenAlexW2011453559WikidataQ52230235 ScholiaQ52230235MaRDI QIDQ4666043
Publication date: 11 April 2005
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2533853
Related Items (38)
A Shrinkage Approach for Estimating a Treatment Effect Using Intermediate Biomarker Data in Clinical Trials ⋮ Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling ⋮ Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time ⋮ Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints ⋮ Bounds on average controlled direct effects with an unobserved response variable ⋮ A comparison of various software tools for dealing with missing data via imputation ⋮ Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model ⋮ On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints ⋮ Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials ⋮ Semiparametric transformation models for semicompeting survival data ⋮ Evaluating multiple surrogate markers with censored data ⋮ A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials ⋮ A joint marginalized multilevel model for longitudinal outcomes ⋮ Bounds on Direct Effects in the Presence of Confounded Intermediate Variables ⋮ Simplified modeling strategies for surrogate validation with multivariate failure-time data ⋮ Evaluating Candidate Principal Surrogate Endpoints ⋮ True endpoint reduction by surrogate endpoints ⋮ Joint Modeling of the Clinical Progression and of the Biomarkers' Dynamics Using a Mechanistic Model ⋮ The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials ⋮ A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials ⋮ Advances in medical statistics arising from the AIDS epidemic ⋮ Surrogate Marker Evaluation from an Information Theory Perspective ⋮ A causal framework for surrogate endpoints with semi-competing risks data ⋮ Quantifying the Effect of the Surrogate Marker by Information Gain ⋮ Estimating Percentile-Specific Treatment Effects in Counterfactual Models: A Case-Study of Micronutrient Supplementation, Birth Weight and Infant Mortality ⋮ Statistical evaluation of surrogate endpoints with examples from cancer clinical trials ⋮ Assessing the value of a censored surrogate outcome ⋮ Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data ⋮ Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics ⋮ A simpler approach for mediation analysis for dichotomous mediators in logistic regression ⋮ Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials ⋮ The Evaluation of Multiple Surrogate Endpoints ⋮ Principal Stratification in Causal Inference ⋮ A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker ⋮ Optimal estimation in surrogate outcome regression problems ⋮ Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS ⋮ On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm ⋮ Linear increment in efficiency with the inclusion of surrogate endpoint
This page was built for publication: Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
